Protagonist Therapeutics Eyes Big Openings in the Market
Analysts have been taking a closer look at Protagonist Therapeutics Inc (NASDAQ: PTGX) as the company advances two lead programs aimed at serious medical conditions. With rusfertide and JNJ-2113 out front, Protagonist is moving through a promising—potentially lucrative—segment of the pharmaceutical landscape.
Two Lead Programs Moving Forward
Rusfertide, the company’s lead drug, has shown encouraging Phase 2 results in a rare blood cancer. Truist Securities has called out its potential as a first-in-class therapy, placing it within a market measured in billions of dollars.
JNJ-2113, an oral IL-23 inhibitor, is also drawing attention for how it’s delivered and how it may perform. It’s the only oral option in its class, which makes it an appealing alternative within its treatment category.
Sales Outlook and Where Demand Is Headed
Truist’s view on rusfertide points to a sizable opportunity: adjusted revenues could reach roughly $660 million for Protagonist Therapeutics at peak. That’s above current consensus and suggests confidence in the drug’s ability to address unmet needs.
The outlook for JNJ-2113 is similarly upbeat. Truist forecasts peak unadjusted end-user sales of $4 billion in psoriasis. For Protagonist, that translates into potential royalties, currently projected at about $300 million.
Why JNJ-2113 Could Shift the Market
Truist notes that JNJ-2113 helps fill gaps across the Inflammation & Immunology (I&I) space—especially where oral treatments are scarce. Given the ongoing demand for effective options to manage conditions like psoriasis, an oral therapy could influence how clinicians prescribe.
There’s also room for JNJ-2113 to move into other indications. Expected trial data in ulcerative colitis in late 2024 adds to its appeal, and analysts expect further readouts to clarify how broadly the therapy can perform across settings.
Stock Snapshot
In the latest market update, PTGX shares traded around $44.96, a modest uptick. That move suggests growing investor confidence as the company’s investigational programs advance.
What to Watch Next
Backed by supportive analysts, Protagonist Therapeutics appears well-placed to pursue value from its pipeline. Focusing on rusfertide and JNJ-2113 highlights both the company’s innovation and its positioning as it pushes into emerging markets.
As trials advance and new data arrive, investors and clinicians alike will be watching how these therapies measure up against competitors—and whether they can turn early promise into durable performance.
Frequently Asked Questions
What are Protagonist Therapeutics’ lead investigational drugs?
Rusfertide and JNJ-2113 are the company’s two lead programs.
How does rusfertide stand out?
It has shown promising Phase 2 results in a rare blood cancer and is viewed by Truist Securities as a potential first-in-class therapy.
What’s unique about JNJ-2113?
It’s the only orally administered IL-23 inhibitor in its class, offering the convenience of a pill versus injection-based options.
What sales are projected for JNJ-2113?
Truist forecasts peak unadjusted end-user sales of about $4 billion in psoriasis, with potential royalties to Protagonist currently projected around $300 million.
How is PTGX stock performing right now?
Shares recently traded near $44.96, reflecting a recent increase of roughly 0.83%.
